EP0934932A1 — Quinoline derivatives and psychotropic agent
Assigned to Meiji Seika Kaisha Ltd · Expires 1999-08-11 · 27y expired
What this patent protects
A psychotropic pharmaceutical composition comprising a compound represented by general formula (I) or a pharmacologically acceptable salt or solvate thereof: wherein m is an integer of 1 to 4, R 1 and R 2 represent a substituent, X represents CH, CH 2 , O, S, SO, or S O 2 , Y…
USPTO Abstract
A psychotropic pharmaceutical composition comprising a compound represented by general formula (I) or a pharmacologically acceptable salt or solvate thereof: wherein m is an integer of 1 to 4, R 1 and R 2 represent a substituent, X represents CH, CH 2 , O, S, SO, or S O 2 , Y and Z each independently represent CH or N, V represents O or -(CH 2 ) n - (wherein n is an integer of 1 to 4), and W represents a group selected from the group consisting of groups (i) to (iii): wherein J represents CH 2 or O, Q represents O, S, or NH, and R 3 and R 4 represent a substituent.
Drugs covered by this patent
- Rexulti (BREXPIPRAZOLE) · Otsuka
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.